BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24873792)

  • 41. Comparison of whole body scintigraphy with Tc-99m-methoxyisobutylisonitrile and iodine-131 NA in patients with differentiated thyroid cancer.
    Al Saleh K; Safwat R; Al-Shammeri I; Abdul Naseer M; Hooda H; Al-Mohannadi S
    Gulf J Oncolog; 2007 Jan; 1(1):29-33. PubMed ID: 20084711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
    Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
    J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
    Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Technetium-99m-pertechnetate whole-body SPET/CT scan in thyroidectomized differentiated thyroid cancer patients is a useful imaging modality in detecting remnant thyroid tissue, nodal and distant metastases before
    Lou K; Gu Y; Hu Y; Wang S; Shi H
    Hell J Nucl Med; 2018; 21(2):121-124. PubMed ID: 30089313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
    Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
    J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tc-99m-tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma--preliminary results.
    Gallowitsch HJ; Kresnik E; Mikosch P; Pipam W; Gomez I; Lind P
    Nuklearmedizin; 1996 Dec; 35(6):230-5. PubMed ID: 8976503
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Scintigraphy with [111In]octreotide and 201Tl in a Hürthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature.
    Kostoglou-Athanassiou I; Pappas A; Gogou L; Kaldrymides P
    Horm Res; 2003; 60(4):205-8. PubMed ID: 14530610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy.
    Nocuń A; Chrapko B; Gołębiewska R; Stefaniak B; Czekajska-Chehab E
    Nucl Med Commun; 2011 Jun; 32(6):522-9. PubMed ID: 21383640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tc-99m MIBI scintigraphy in tall cell variant of papillary thyroid carcinoma with negative radioiodine scan.
    Kaya M; Cermik TF
    Clin Nucl Med; 2008 Sep; 33(9):615-8. PubMed ID: 18716510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiac pheochromocytomas detected by Tc-99m-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) scintigraphy.
    Chen L; Li F; Zhuang H; Jing H; Du Y; Zeng Z
    Clin Nucl Med; 2007 Mar; 32(3):182-5. PubMed ID: 17314591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan.
    Baudin E; Schlumberger M; Lumbroso J; Travagli JP; Caillou B; Parmentier C
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2541-4. PubMed ID: 8675574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Value of scintigraphic explorations by radiomarkers others than iodine radioisotope in differentiated thyroid cancer].
    Sassolas G; Houzard C; Sigartau C; Borson-Chazot F
    Ann Endocrinol (Paris); 1997; 58(1):55-63. PubMed ID: 9207967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
    Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incremental value of
    Trogrlic M; Težak S
    Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer.
    Rubello D; Salvatori M; Casara D; Piotto A; Toniato A; Gross MD; Al-Nahhas A; Muzzio PC; Pelizzo MR
    Eur J Surg Oncol; 2007 Sep; 33(7):902-6. PubMed ID: 17267163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.